Aspen Aerogels, Inc.
NYSE:ASPNConstruction
+$0.24 today
- Market cap
- $407.33M
- Beta
- 2.99
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.35
Volume 1.17M
Average 1.58M
ASPN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Aspen Aerogels, Inc.NYSE: ASPN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$20.64M, compared with -$292.42M a year earlier. Trailing-twelve-month EBITDA was -$59.51M.
Context
- EBITDA amounted to 2108.3% of revenue in FY2025, up 2096.9 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $2.5M (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +11007.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.64M+51.0% QoQ
- Last fiscal yearDec 2025
- $5.72B+11007.0% YoY
- LTMMar 2026
- -$59.51M+76.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +92.9% | -1945.8% | -2038.7 pp |
| 1 year | +11007.0% | -100.0% | -11107.0 pp |
| 3-year CAGR | — | -70.3% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 5.72B USD
- Year-over-year change
- +11007.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.72B | +11007.0% |
| FY2024 | 2024-12-31 | 51.46M | +330.7% |
| FY2023 | 2023-12-31 | (22.31M) | +67.4% |
| FY2022 | 2022-12-31 | (68.41M) | -149.4% |
| FY2021 | 2021-12-31 | (27.43M) | — |
EBITDA vs competitors
How ASPN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +76.2% is the 2nd highest of 10, against a peer median of -16.1%.
- EBITDA amounts to 25.8% of revenue for ASPN, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Feb 2026 | $159.29M USD | -13.8% | -5.6% | 11.3% | |
| LTM Mar 2026 | $105.75M USD | +23.1% | — | 17.8% | |
| LTM Apr 2026 | $69.01M USD | -36.5% | -46.2% | 2.3% | |
| FY2025 | -€2.24M EUR | +97.0% | — | 7.1% | |
| LTM Mar 2026 | -$8.4M USD | -103.5% | +55.1% | 0.2% | |
| LTM Mar 2026 | -$8.59M USD | -250.9% | — | 4.1% | |
| LTM Mar 2026 | -$15.95M USD | -16.1% | — | — | |
| LTM Mar 2026 | -$59.51M USD | +76.2% | — | 25.8% | |
| LTM Apr 2026 | -$85.76M USD | -157.1% | — | 4.6% | |
| LTM Mar 2026 | -CN¥257.52M CNY | -9.5% | — | 61.7% | |
| Peer median (excluding ASPN) | — | -16.1% | -5.6% | 5.9% | |
Competitors are the stored peer set for ASPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 121.62M | 180.36M | 238.72M | 452.7M | 271.1M |
| Cost of Revenue | 111.69M | 175.39M | 181.8M | 269.8M | 225.11M |
| Gross Profit | 9.94M | 4.98M | 56.92M | 182.9M | 46M |
| Gross Margin | 8.2% | 2.8% | 23.8% | 40.4% | 17.0% |
| Research & Development | 11.44M | 16.93M | 16.36M | 18.05M | 6.3B |
| Selling, General & Admin | 39.1M | 67.29M | 89.77M | 106.8M | 40.91B |
| Operating Expenses | 50.54M | 84.22M | 106.12M | 128.36M | 97.39M |
| Depreciation & Amortization | 9.44M | 9.22M | 18.18M | 24.41M | 45.16M |
| EBITDA | (27.43M) | (68.41M) | (22.31M) | 51.46M | 5.72B |
| EBITDA Margin | -22.5% | -37.9% | -9.3% | 11.4% | 2108.3% |
| Operating Income | (40.6M) | (79.25M) | (49.2M) | 54.54M | (51.39M) |
| Operating Margin | -33.4% | -43.9% | -20.6% | 12.0% | -19.0% |
| Interest Income | 0 | 1.62M | 6.53M | 0 | 0 |
| Interest Expense | 229K | 5.11M | 5.33M | 11.96M | 6.06B |
| Other Income / Expenses | 3.51M | (3.49M) | 3.39M | (39.45M) | (335.77M) |
| Income Before Tax | (37.09M) | (82.74M) | (45.81M) | 15.09M | (387.16M) |
| Pre-Tax Margin | -30.5% | -45.9% | -19.2% | 3.3% | -142.8% |
| Income Tax Expense | 0 | 0 | 0 | 1.71M | 2.39M |
| Net Income | (37.09M) | (82.74M) | (45.81M) | 13.38M | (389.55M) |
| Net Margin | -30.5% | -45.9% | -19.2% | 3.0% | -143.7% |
| EPS (Basic) | (0.92) | (2.19) | (0.66) | 0.17 | (4.74) |
| EPS (Diluted) | (0.92) | (2.19) | (0.66) | 0.17 | (4.74) |
| Weighted Avg Shares | 30.43M | 39.36M | 69.44M | 77.54M | 82.66M |
| Weighted Avg Shares (Diluted) | 30.43M | 39.36M | 69.44M | 80.31M | 82.66M |
Aspen Aerogels, Inc.
NYSE:ASPN
Intrinsic Alpha fair value
Locked
Current Price
$4.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.